SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending as the community discusses its recent performance following earnings, with debates focusing on revenue projections and the impact of short reports. Some traders believe the stock is poised for a short squeeze, citing high short interest and positive analyst ratings, while others express concerns about the company's financials and question its AI capabilities. The community is closely monitoring price movements and potential catalysts, including upcoming news related to crypto payments.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to a broader crypto market rally and recent strategic restructuring, including the sale of its loyalty business and appointment of a fintech veteran to its board. The community is actively discussing the potential for a short squeeze and the company's transformation into a pure-play digital asset platform. Bullish sentiment is growing, with some eyeing prior highs and speculating about future partnerships and expansion.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates potential ETF approvals and discusses its ability to break the $3 resistance level; some see the government shutdown as a potential catalyst. Despite positive sentiment and news, some traders express frustration with XRP's price action compared to other cryptocurrencies. The community debates its utility, future price predictions, and the implications of recent Ripple leadership changes.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending downwards as the community debates the impact of reduced reliance on Reddit data by ChatGPT and other AI models. Some traders believe the stock is oversold and due for a rebound, while others express concerns about its long-term value and potential for further decline. Community members are closely watching key support levels and discussing possible manipulation by hedge funds.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending due to a mix of positive price action and news of increased competition in the stablecoin space. Community members are debating whether the stock will continue its upward momentum or face a pullback due to potential rate cuts impacting revenue. Traders are actively discussing technical levels and potential short squeezes, with some highlighting the impact of insider selling and upcoming share unlock.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding Limited - ADR ($BQ) is trending due to significant price volatility and multiple trading halts, sparking discussions about potential pump-and-dump schemes. The community is actively debating the reasons behind the stock's sudden surge, with some speculating about possible multi-day runner potential and others warning of an impending crash. This activity occurs within a broader context of traders seeking quick gains in low-float stocks, with comparisons being drawn to similar situations in other Chinese companies.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst is trending as investors discuss the recent Evercore downgrade and the completion of the sale of its European ORLADEYO business, leading to mixed reactions. Community sentiment is divided, with some expressing frustration over the stock's performance and others highlighting the company's fundamentals and potential for a buyout or share buyback. The conversation includes speculation about future acquisitions, pipeline developments, and the impact of competition in the HAE market.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss potential catalysts, including upcoming data presentations at the World Muscle Society (WMS) Congress and the anticipation of positive news regarding SRP-9003. Community members are weighing the potential for a short squeeze given the stock's high short interest, with some expressing optimism for a significant price increase and buyout speculation, while remaining cautiously optimistic.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's Q3 delivery numbers beat estimates, but the stock is down, sparking debate on whether this was a "sell the news" event or a sign of concerns about future growth and the end of EV tax credits; the community is actively discussing potential support levels and the impact of Elon Musk's actions on the stock.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending as investors react to Berkshire Hathaway's acquisition of OXY's OxyChem unit, leading to discussions around debt reduction and potential share buybacks. Community perspectives are mixed, with some questioning the strategic rationale behind selling a profitable business unit while others see it as a necessary step to strengthen the balance sheet. The news has sparked debate about the company's future direction and exposure to oil price fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported that its oral drug Simufilam did not yield positive results in patients with mild to moderate Alzheimer’s disease in its second Phase 3 study.The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said.Cassava added that it would discontinue the Alzheimer’s disease development program with Simufilam by the end of the second quarter of 2025. &nbsp;REFOCUS-ALZ was discontinued on Nov. 25 last year after the company identified that a previous phase 3 study failed to yield positive results.Cassava CEO Rick Barry acknowledged the results were "unambiguous" and added that the company was “disappointed.”“Cassava will discontinue all efforts to develop Simufilam for Alzheimer’s disease, and we expect to phase out the program by the end of Q2 2025,” he said.The CEO added that the company has initiated preclinical studies to gauge the potential of Simufilam in treating TSC-related epilepsy.Company CFO Eric Schoen said the firm continues to be committed to enhancing shareholder value. “Cassava is well-capitalized with approximately $128.6 million in cash and cash equivalents as of Dec. 31, 2024,” he added.Cassava reported a net loss of $27.60 million in the three months ended December 2024 compared to a net loss of $20.92 million in the corresponding quarter of 2023.On Stocktwits, retail sentiment about Cassava Sciences climbed further into the ‘bullish’ territory (60/100), while message volume jumped from ‘normal’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:650/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_25_at_1_50_58_PM_png_d88af5aac9.webp" alt="SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits" width="650" height="146"><figcaption>SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expects the share price to drop further in the coming days.<stembedurl>https://stocktwits.com/pg3015/message/609181500</stembedurl>Another user expressed optimism, highlighting the company’s debt-free status.<stembedurl>https://stocktwits.com/mcrotary/message/609180826</stembedurl>SAVA stock has lost over 30% this year and is down by over 90% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/merck-enters-license-agreement-with-china-based-hengrui-pharma/ch7yxJsRbdw">Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful

The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025. 

Equity

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc...

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA Cassava Sciences, Inc. Securities Fraud Class...

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm Lead Plaintiff Deadline on February 10, 2025...

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff...

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to...

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA Cassava Sciences, Inc. Sued for Securities Law Violations...

SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$3.30
Prev Close	$3.20
Open	$3.23
Dividend Yield	0.00%
50-Day Moving Average	$2.37
Beta	0.96
Avg. Volume	4.27M
PE Ratio	-1.25

52-Week High	$33.98
52-Week Low	$1.15
Market Capitalization	$154.59M
EPS (Annual)	-$1.46
Price to Book	1.76
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAVA News

SAVA Cassava Sciences Inc